Skip to main content
. Author manuscript; available in PMC: 2012 Jun 26.
Published in final edited form as: Biol Blood Marrow Transplant. 2010 Mar 19;16(9):1245–1256. doi: 10.1016/j.bbmt.2010.03.014

Figure 4. Transgene rejection response detected when T cells administered following hematopoietic stem cell transfer.

Figure 4

In the trial targeting CD20+ diffuse large cell lymphoma, PBMC collected prior to treatment and at day 75 (UPN006) or day 77 (UPN009) after initiation of treatment were stimulated in vitro with irradiated LCL as a control (xLCL) or the corresponding irradiated CTL clone that had been administered (i.e., x1A11 or x6D10). Effectors were then used in a 4-hour 51Cr-release assay using either LCL or the corresponding CTL as targets (A) or, in the case of UPN009, using LCL that had been transfected with the pcDNA3.1(−) vector lacking the CD20R transgene as targets (B). (C), Clones derived from UPN009 day 98 PBMC were also stimulated in vitro with irradiated 6D10 CTL and then analyzed for cytolytic activity against 51Cr-labeled LCL, 6D10 or pcDNA3.1(−) vector transfected LCL to determine specificity of transgene-specific response. Percent 51Cr-release at an E:T of 25:1 in each case is depicted for four representative clones.